Citigroup Maintains Buy on PTC Therapeutics, Raises Price Target to $109

Benzinga · 1d ago
Citigroup analyst Eric Joseph maintains PTC Therapeutics (NASDAQ:PTCT) with a Buy and raises the price target from $108 to $109.